0001209191-17-042197.txt : 20170628 0001209191-17-042197.hdr.sgml : 20170628 20170628204540 ACCESSION NUMBER: 0001209191-17-042197 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170628 FILED AS OF DATE: 20170628 DATE AS OF CHANGE: 20170628 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2530 MERIDIAN PARKWAY STREET 2: SUITE 300 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 2530 MERIDIAN PARKWAY STREET 2: SUITE 300 CITY: DURHAM STATE: NC ZIP: 27713 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Novak Alfred J CENTRAL INDEX KEY: 0001388862 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 17936592 MAIL ADDRESS: STREET 1: 325 NE 6TH ST CITY: BOCA RATON STATE: FL ZIP: 33432 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2017-06-28 0 0001685071 Dova Pharmaceuticals, Inc. DOVA 0001388862 Novak Alfred J C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 1 0 0 0 Common Stock 0 D Stock Option (Right to Buy) 7.32 2027-05-24 Common Stock 33000 D The option shall vest over a period of three years as follows: (i) one-third of the total shares subject to the option shall vest on May 25, 2018, and (ii) 1/36th of total shares subject to the option shall vest monthly thereafter over the remaining two years of the vesting period, subject to the Reporting Person's continuous service with the Issuer on each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock. Exhibit List - Exhibit 24 - Power of Attorney /s/ Jason Saxe, Attorney-in-Fact 2017-06-28 EX-24.3_733554 2 poa.txt POA DOCUMENT POWER OF ATTORNEY (For Executing Form ID and Forms 3, 4 and 5) Know all by these presents, that the undersigned hereby constitutes and appoints each of Darren DeStefano, Mark Ballantyne, Jason Saxe and Jill Simon of Cooley LLP, and Douglas Blankenship of Dova Pharmaceuticals, Inc. (the "Company"), signing individually, the undersigned's true and lawful attorneys-in fact and agents to: (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the the Securities and Exchange Commission (the "SEC") Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company; (2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and (3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion. The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Form ID or Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP, as applicable. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below. Date: June 8, 2017 By: /s/ Alfred J. Novak Alfred J. Novak